NO20010576L - Immunologiske herpes simplex virus antigener og fremgangsmÕter for anvendelse derav - Google Patents

Immunologiske herpes simplex virus antigener og fremgangsmÕter for anvendelse derav

Info

Publication number
NO20010576L
NO20010576L NO20010576A NO20010576A NO20010576L NO 20010576 L NO20010576 L NO 20010576L NO 20010576 A NO20010576 A NO 20010576A NO 20010576 A NO20010576 A NO 20010576A NO 20010576 L NO20010576 L NO 20010576L
Authority
NO
Norway
Prior art keywords
antigens
hsv
cells
immunological
methods
Prior art date
Application number
NO20010576A
Other languages
English (en)
Other versions
NO20010576D0 (no
Inventor
David M Koelle
Lawrence Corey
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Publication of NO20010576D0 publication Critical patent/NO20010576D0/no
Publication of NO20010576L publication Critical patent/NO20010576L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Oppfinnelsen tilveiebringer HSV antigener som er nyttige for å forebygge og behandle HSV infeksjon. Angitt heri er antigener og/eller deres konstituente epitoper bekreftet å være gjenkjent av T-celler avledet fra herpes lesjoner eller fra livmorhalsen. T-celler som har spesifisitet for antigenene fra oppfinnelsen har vist cytotoksisk aktivitet mot celler som har viral-kodede peptid epitoper, og i mange tilfeller, mot celler infisert med HSV. Identifiseringen av immunogene antigener som er ansvarlig for T-celle spesifisitet tilveiebringer forbedret antiviral terapeutika og profylaktiske strategier. Sammensetninger som inneholder antigener eller polynukleotider som koder for antigener fra oppfinnelsen tilveiebringer effektive mål økende vaksiner for å forebygge og behandle HSV infeksjon.
NO20010576A 1998-08-07 2001-02-02 Immunologiske herpes simplex virus antigener og fremgangsmÕter for anvendelse derav NO20010576L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9572498P 1998-08-07 1998-08-07
US9572398P 1998-08-07 1998-08-07
PCT/US1999/017803 WO2000008051A2 (en) 1998-08-07 1999-08-05 Immunological herpes simplex virus antigens and methods for use thereof

Publications (2)

Publication Number Publication Date
NO20010576D0 NO20010576D0 (no) 2001-02-02
NO20010576L true NO20010576L (no) 2001-04-02

Family

ID=26790525

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20010576A NO20010576L (no) 1998-08-07 2001-02-02 Immunologiske herpes simplex virus antigener og fremgangsmÕter for anvendelse derav

Country Status (16)

Country Link
US (5) US6375952B1 (no)
EP (2) EP1102790B1 (no)
JP (1) JP2002522451A (no)
KR (1) KR20010085348A (no)
CN (1) CN1348463A (no)
AR (1) AR020134A1 (no)
AU (1) AU5467899A (no)
BR (1) BR9912671A (no)
CA (1) CA2336523C (no)
DK (1) DK2272859T3 (no)
IL (1) IL141044A0 (no)
NO (1) NO20010576L (no)
NZ (1) NZ509974A (no)
PL (1) PL346213A1 (no)
TR (1) TR200100373T2 (no)
WO (1) WO2000008051A2 (no)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060024301A1 (en) * 1997-02-25 2006-02-02 Corixa Corporation Prostate-specific polypeptides and fusion polypeptides thereof
US20030185830A1 (en) * 1997-02-25 2003-10-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7517952B1 (en) 1997-02-25 2009-04-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
BR9912671A (pt) * 1998-08-07 2001-05-02 Univ Washington Antìgenos imunológicos para o vìrus de herpes simples e métodos para sua utilização
US7223593B2 (en) 2000-01-21 2007-05-29 Biovex Limited Herpes virus strains for gene therapy
US7217770B2 (en) * 2000-05-17 2007-05-15 Samyang Corporation Stable polymeric micelle-type drug composition and method for the preparation thereof
US6821519B2 (en) * 2000-06-29 2004-11-23 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
US7048931B1 (en) * 2000-11-09 2006-05-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
WO2003011893A2 (en) * 2001-07-31 2003-02-13 University Of Washington Immunologically significant herpes simplex virus antigens and methods for using same
EP2011510B1 (en) 2002-07-18 2011-01-12 University of Washington Pharmaceutical compositions comprising immunologically active herpes simplex virus (HSV) protein fragments
JP2007505147A (ja) * 2003-09-12 2007-03-08 アンティジェニクス インコーポレーテッド 単純ヘルペスウイルス感染の治療および予防用ワクチン
US7211272B2 (en) * 2003-12-22 2007-05-01 Bausch & Lomb Incorporated Drug delivery device
CA2658484A1 (en) 2006-07-20 2008-01-24 Vical Incorporated Compositions and methods for vaccinating against hsv-2
US8871223B2 (en) * 2006-09-08 2014-10-28 The Trustees Of The University Of Pennsylvania HSV-1 and HSV-2 vaccines and methods of use thereof
WO2008124055A1 (en) 2007-04-04 2008-10-16 The Board Of Trustees Of The University Of Arkansas Non-specific delayed-type hypersensitivity response to treat herpes simplex virus infection
US8460674B2 (en) * 2009-02-07 2013-06-11 University Of Washington HSV-1 epitopes and methods for using same
WO2010115172A2 (en) 2009-04-03 2010-10-07 University Of Washington Antigenic peptide of hsv-2 and methods for using same
RU2585961C9 (ru) 2009-05-22 2016-12-27 Дженосеа Биосайенсиз Инк. Вакцины против вируса простого герпеса 2 типа: композиции и способы запуска иммунного ответа
WO2012061637A2 (en) * 2010-11-03 2012-05-10 University Of Washington Hsv-1 epitopes and methods for using same
AU2011336894B2 (en) 2010-11-24 2016-11-17 Genocea Biosciences, Inc. Vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response
AU2012217723A1 (en) 2011-02-15 2013-08-29 Immune Design Corp. Methods for enhancing immunogen specific immune responses by vectored vaccines
CA2832307A1 (en) * 2011-04-08 2012-10-18 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
WO2012149307A2 (en) * 2011-04-27 2012-11-01 Immune Design Corp. Synthetic long peptide (slp)-based vaccines
JP6205360B2 (ja) 2011-08-22 2017-09-27 ナノバイオ コーポレーション 単純ヘルペスウイルスのナノエマルジョンワクチン
CA2885693C (en) 2011-11-23 2020-07-28 Genocea Biosciences, Inc. Nucleic acid vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
EP2850431B1 (en) * 2012-05-16 2018-04-18 Immune Design Corp. Vaccines for hsv-2
WO2014164699A1 (en) * 2013-03-11 2014-10-09 The Regents Of The University Of California Herpes virus vaccines and treatments
CA2939093A1 (en) 2014-02-14 2015-08-20 Immune Design Corp. Immunotherapy of cancer through combination of local and systemic immune stimulation
US20170196954A1 (en) 2014-07-15 2017-07-13 Immune Design Corp. Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector
KR20160073707A (ko) 2014-12-17 2016-06-27 삼성중공업 주식회사 액화천연가스 운반선의 운용방법
JP6760973B2 (ja) 2015-02-26 2020-09-23 スクエアエックス、 エルエルシー 単純ヘルペスウイルス感染治療のための非特異的遅延型過敏反応
RS62747B1 (sr) * 2016-02-01 2022-01-31 Simplexia Ab Skraćeni glikoprotein g herpes simpleks virusa 2
EP3429619A1 (en) * 2016-03-14 2019-01-23 Redbiotec AG Means and methods for treating hsv
KR20190006495A (ko) 2016-04-15 2019-01-18 알파인 이뮨 사이언시즈, 인코포레이티드 Cd80 변이체 면역조절 단백질 및 그의 용도
AU2017250358B2 (en) 2016-04-15 2023-06-01 Alpine Immune Sciences, Inc. ICOS ligand variant immunomodulatory proteins and uses thereof
WO2018022945A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd112 variant immunomodulatory proteins and uses thereof
CN110088127A (zh) 2016-07-28 2019-08-02 高山免疫科学股份有限公司 Cd155变体免疫调节蛋白及其用途
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
WO2018064232A1 (en) 2016-09-28 2018-04-05 Genocea Biosciences, Inc. Methods and compositions for treating herpes
JP2020511144A (ja) 2017-03-16 2020-04-16 アルパイン イミューン サイエンシズ インコーポレイテッド Ｐｄ−ｌ２バリアント免疫調節タンパク質及びその使用
BR112019018747A2 (pt) 2017-03-16 2020-05-05 Alpine Immune Sciences Inc proteínas imunomoduladoras variantes de cd80 e usos das mesmas
CA3053804A1 (en) 2017-03-16 2018-09-20 Alpine Immune Sciences, Inc. Pd-l1 variant immunomodulatory proteins and uses thereof
CN110506060B (zh) 2017-03-30 2024-05-07 昆士兰大学 嵌合分子及其用途
US20190031739A1 (en) * 2017-07-30 2019-01-31 Raymond Joel Rairie Pinball herpes antibody system
EP3687561A4 (en) 2017-09-01 2021-06-09 The Australian National University IMMUN REGULATORY MOLECULES AND THEIR USES
KR20230020022A (ko) 2017-10-10 2023-02-09 알파인 이뮨 사이언시즈, 인코포레이티드 Ctla-4 변이체 면역조절 단백질 및 이의 용도
KR20200085777A (ko) 2017-10-18 2020-07-15 알파인 이뮨 사이언시즈, 인코포레이티드 변이체 icos 리간드 면역조절 단백질 및 관련 조성물 및 방법
CA3087149A1 (en) 2018-01-03 2019-07-11 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
WO2019241758A1 (en) 2018-06-15 2019-12-19 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof
SG11202102644XA (en) 2018-09-19 2021-04-29 Alpine Immune Sciences Inc Methods and uses of variant cd80 fusion proteins and related constructs
CN113727998A (zh) 2018-11-30 2021-11-30 高山免疫科学股份有限公司 Cd86变体免疫调节蛋白及其用途
BR112021020447A2 (pt) 2019-04-17 2022-05-17 Alpine Immune Sciences Inc Métodos e usos de proteínas de fusão de ligante icos variante (icosl)
KR20230029622A (ko) 2020-05-08 2023-03-03 알파인 이뮨 사이언시즈, 인코포레이티드 April 및 baff 억제 면역조절 단백질 및 사용 방법
IL308336A (en) 2021-05-07 2024-01-01 Alpine Immune Sciences Inc Methods of dosing and treatment with TACI-FC modulatory fusion protein
WO2023172883A1 (en) 2022-03-07 2023-09-14 Alpine Immune Sciences, Inc. Immunomodulatory proteins of variant cd80 polypeptides, cell therapies thereof and related methods and uses
CN115808528B (zh) * 2022-09-21 2023-08-01 武汉滨会生物科技股份有限公司 溶瘤单纯疱疹病毒vp5蛋白与人白细胞抗原e的互作方法及应用
WO2024077018A2 (en) 2022-10-04 2024-04-11 Alpine Immune Sciences, Inc. Methods and uses of taci-fc fusion immunomodulatory protein

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4429008B1 (en) 1981-12-10 1995-05-16 Univ California Thiol reactive liposomes
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
JPS59116229A (ja) 1982-12-24 1984-07-05 Teijin Ltd 細胞毒性複合体を活性成分とする癌治療用剤およびその製造法
US4873088A (en) 1983-09-06 1989-10-10 Liposome Technology, Inc. Liposome drug delivery method and composition
US4859587A (en) 1984-06-04 1989-08-22 Institut Merieux Recombinant herpes simplex viruses, vaccines and methods
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
EP0297924A3 (en) * 1987-07-01 1990-07-11 City Of Hope Recombinant vaccinia virus expressing hsv 1 gb
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
WO1989001973A2 (en) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
WO1991002805A2 (en) 1989-08-18 1991-03-07 Viagene, Inc. Recombinant retroviruses delivering vector constructs to target cells
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
EP0541692B1 (en) 1990-08-02 1999-05-06 Chiron Corporation Herpes simplex virus vp16 vaccines
JPH05236967A (ja) * 1991-05-07 1993-09-17 Medical Res Council ヘルペスウイルス粒子及びワクチン
CA2090295A1 (en) 1992-02-03 1993-08-04 Anthony B. Nesburn Process for the expression of herpes simplex virus type 1 glycoprotein e and methods of use
ES2108278T3 (es) 1992-06-25 1997-12-16 Smithkline Beecham Biolog Composicion de vacuna con coadyuvantes.
US5426039A (en) 1993-09-08 1995-06-20 Bio-Rad Laboratories, Inc. Direct molecular cloning of primer extended DNA containing an alkane diol
GB9325496D0 (en) * 1993-12-14 1994-02-16 Smithkline Beecham Biolog Vaccines
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
ATE328890T1 (de) 1994-07-15 2006-06-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
AU711121B2 (en) * 1995-02-21 1999-10-07 Cantab Pharmaceuticals Research Limited Viral preparations, vectors, immunogens, and vaccines
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
JPH11510386A (ja) 1995-07-28 1999-09-14 マリー キュリー キャンサー ケア 輸送蛋白質およびそれらの使用
WO1997024447A1 (en) 1996-01-02 1997-07-10 Chiron Corporation Immunostimulation mediated by gene-modified dendritic cells
GB9615726D0 (en) * 1996-07-26 1996-09-04 Medical Res Council Anti-viral agent 11
EP0948508A4 (en) * 1996-11-04 2001-11-07 Smithkline Beecham Corp NEW CODING SEQUENCES FOR HERPES SIMPLEX TYPE 2 VIRUS
CA2291010A1 (en) * 1997-06-02 1998-12-10 Chiron Corporation Herpes simplex virus vp22 vaccines and methods of use
BR9912671A (pt) * 1998-08-07 2001-05-02 Univ Washington Antìgenos imunológicos para o vìrus de herpes simples e métodos para sua utilização
GB9825953D0 (en) * 1998-11-26 1999-01-20 Medical Res Council Protein fragments for use in protein targeting
CA2379623C (en) * 1999-09-30 2014-09-09 University Of Washington Immunologically significant herpes simplex virus antigens
US6821519B2 (en) 2000-06-29 2004-11-23 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
EP2011510B1 (en) * 2002-07-18 2011-01-12 University of Washington Pharmaceutical compositions comprising immunologically active herpes simplex virus (HSV) protein fragments
CA2658484A1 (en) 2006-07-20 2008-01-24 Vical Incorporated Compositions and methods for vaccinating against hsv-2
US8865185B2 (en) 2006-09-08 2014-10-21 The Trustees Of The University Of Pennsylvania Methods of use for HSV-1 and HSV-2 vaccines

Also Published As

Publication number Publication date
BR9912671A (pt) 2001-05-02
NZ509974A (en) 2003-10-31
EP1102790A2 (en) 2001-05-30
KR20010085348A (ko) 2001-09-07
WO2000008051A2 (en) 2000-02-17
US8852602B2 (en) 2014-10-07
US20100215693A1 (en) 2010-08-26
EP2272859B1 (en) 2014-10-22
AU5467899A (en) 2000-02-28
CA2336523C (en) 2015-06-30
US7744903B2 (en) 2010-06-29
US20030118611A1 (en) 2003-06-26
JP2002522451A (ja) 2002-07-23
CN1348463A (zh) 2002-05-08
DK2272859T3 (en) 2015-01-19
US8067010B2 (en) 2011-11-29
NO20010576D0 (no) 2001-02-02
TR200100373T2 (tr) 2001-09-21
US20050163794A1 (en) 2005-07-28
IL141044A0 (en) 2002-02-10
US6375952B1 (en) 2002-04-23
US6855317B2 (en) 2005-02-15
EP2272859A3 (en) 2011-06-08
EP1102790B1 (en) 2014-05-07
WO2000008051A3 (en) 2000-08-03
CA2336523A1 (en) 2000-02-17
EP2272859A2 (en) 2011-01-12
AR020134A1 (es) 2002-04-10
PL346213A1 (en) 2002-01-28
US20120027790A1 (en) 2012-02-02

Similar Documents

Publication Publication Date Title
NO20010576L (no) Immunologiske herpes simplex virus antigener og fremgangsmÕter for anvendelse derav
BR0014408A (pt) Antìgenos do vìrus do herpes simples imunologicamente significativos; e métodos para identificação e utilização dos mesmos
Vollmar et al. Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine
Clements et al. The epidemiology of measles: thirty years of vaccination
ES2224655T3 (es) Vacuna antiviral recombinante de la encefalitis equina venezolana.
FR16C0026I1 (no)
WO2003011893A3 (en) Immunologically significant herpes simplex virus antigens and methods for using same
DK1349926T3 (da) Komplementerende cellelinier
NO331825B1 (no) HPV viruslignende partikkel samt vaksine
EA027784B1 (ru) Комбинированная вакцина против кори и вируса папилломы человека
ATE179614T1 (de) Herpes simplex virus vp16 impfstoffe
UA84667C2 (ru) Вакцина, направленная против инфекции, вызванной вирусом герпеса болезни марека
WO2009150281A1 (es) Empleo de lauril galato en la prevención y tratamiento de infecciones causadas por el virus de la peste porcina africana (vppa)
Fernández‐Parrado et al. Monkeypox vaccine: Special considerations for dermatologic patients.
CA2245545A1 (en) Vaccines against varicella zoster virus gene 63 product
US20240156951A1 (en) Vaccine compositions and methods for treating hsv
HU228401B1 (en) Smallpox vaccine
WO2004009763A2 (en) Use of vaccinia virus deleted for the e3l gene as a vaccine vector
Lasky From virus to vaccine: recombinant mammalian cell lines as substrates for the production of herpes simplex virus vaccines
Thomson IMMUNOLOGICAL AND PROTECTIVE RESPONSES TO A HERPES SIMPLEX VIRUS SUBUNIT VACCINE IN A LABIAL INFECTION MODEL IN MICE.
WO2003017943A3 (en) Therapeutic compositions and methods for treating viral infection
Hanke Vehicles for Genetic Vaccines Against Human Immunodeficiency Virus Induction of T Cell-mediated Immune Responses
Rooney et al. Prospects for treatment and prevention of latent herpes simplex virus infection
Kapoor et al. Effect of certain purine and pyrimidine analogues on growth, nucleic acid synthesis and ultraviolet-induced lysis in Vibrio cholerae
AU2390101A (en) Toscana virus nucleoprotein